After a median follow-up of 163 months ( IQR 144-268 ) in the cisplatin plus gemcitabine group and 159 months ( 107-254 ) in the paclitaxel plus gemcitabine group , the hazard ratio for progression-free survival was 0692 ( 95 % CI 0523-0915 ; pnon-inferiority < 00001 , psuperiority = 0009 , thus cisplatin plus gemcitabine was both non-inferior to and superior to paclitaxel plus gemcitabine .